Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence i
- PDF / 902,867 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 102 Downloads / 123 Views
ORIGINAL ARTICLE
Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow‑up study in Japan Atsushi Ikeda1 · Takahiro Kojima1 · Koji Kawai1 · Shiro Hinotsu2 · Naoto Keino3 · Kenichiro Shiga4 · Hideaki Miyake5 · Yasuyoshi Miyata6 · Yutaka Enomoto7 · Fumitaka Shimizu8 · Satoshi Anai9 · Hideyasu Matsuyama10 · Chieko Suzuki11 · Yusuke Kanimoto12 · Keisuke Shigeta13 · Seiji Naito4 · Hideyuki Akaza14 · Hiroyuki Nishiyama1 Received: 25 November 2019 / Accepted: 5 February 2020 © The Author(s) 2020
Abstract Background A previous comparative study in Japan has demonstrated that the two consecutive UroVysion tests are useful tools to detect the presence of bladder cancer during follow-up after transurethral resection, but they also presented their high rates of false-positive results. Here, we aimed to evaluate the relationship between the UroVysion tests and subsequent intravesical recurrence. Methods In the previous study, patients without bladder cancer during the first analysis showed the same examination set repeated 3 months later as the second analysis. In this follow-up study, 326 patients showed negative findings confirmed on cystoscopy during the second UroVysion test. Recurrence-free survival was assessed using a median follow-up of 27 months. Results In the two consecutive UroVysion tests, 214 patients (65.6%) showed negative UroVysion results in both tests, whereas 91 presented a positive result on either tests and 21 patients presented positive results in both tests. During the follow-up, 40 patients (12.3%) had an intravesical recurrence with non-muscle-invasive bladder cancer. The recurrence rates in patients with negative results in both tests, those with one positive result in either tests, and those with positive results in both tests were 8.4%, 16.5%, and 33.3%, respectively. The multivariate analysis indicated that the history of bladder cancer and the consecutive UroVysion test pattern were independent risk factors for recurrence. Conclusions Our data confirmed the effectiveness of two consecutive UroVysion tests in predicting intravesical recurrence after TURBT. Further prospective studies would help determine an appropriate interval for cystoscopy follow-up. Keywords UroVysion · Non-muscle-invasive bladder cancer · Intravesical recurrence
* Hiroyuki Nishiyama [email protected] 1
Department of Urology, University of Tsukuba, 1‑1‑1 Tennodai, Tsukuba, Ibaraki 3058575, Japan
Department of Biostatistics, Sapporo Medical University, Sapporo, Japan
2
3
4
Tsukuba Clinical Research and Development Organization (T‑CReDO), University of Tsukuba, Tsukuba, Japan Department of Urology, Harasanshin Hospital, Fukuoka, Japan
5
Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
6
Department of Urology, Nagasaki University, Nagasaki, Japan
7
Department of Urology, Mitsui Memorial Hospital, Tokyo, Japan
8
Department of Urology, J
Data Loading...
